Marinus Pharmaceuticals(MRNS) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results ● ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56$33 to $34 million ● Reported results from Phase 3 TrustTSC trial and commenced process to explore strategic alternatives ● Marinus continues to support the commercial growth of ZTALMY; further ganaxolone clinical development ...